Research article · 15 Apr 2026
Conference abstractPublished 14 May 2018
The role of IL-1 in anemia of chronic kidney disease
Ben Gurion University of the Negev, Israel Schneider Children's Medical Center, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Anemia of chronic kidney disease (CKD) may be due to impaired renal erythropoietin (EPO) synthesis, EPO resistance and hepcidin mediated iron malabsorption. Interleukin (IL-1), an important pro-inflammatory cytokine, is normally controlled by a receptor antagonist (IL1Ra). IL1Ra-KO (RaKO) mice show arthritis and excessive inflammation. The aim of this study was to characterize the anemic state of RaKO mice with CKD. RaKO and wild type (WT) mice were divided into four groups: WT-C, WT-CKD, RaKO-C, RaKO-CKD. CKD or control states were induced by 5/6 nephrectomy or sham operations. Mice were sacrificed after 12 weeks from surgery. RaKO animals developed chronic arthritis, in association with increased levels of liver CRP and kidney IL6. Serum creatinine and urea levels were similar in the 2 CKD groups, but RaKO-CKD had higher degrees of renal inflammation and fibrosis vs. WT-CKD. Hematocrit levels were decreased only in RaKO-CKD (but not in WT-CKD). Serum iron levels were reduced in both RaKO groups and were even lower in RaKO-CKD vs. RaKO-C. Liver hepcidin mRNA levels were equally increased in both RaKO groups vs. WT-C, but were more increased in WT-CKD vs. RaKO. Renal HIF2 levels were not increased in RaKO CKD. Bone marrow EPO-R mRNA levels were significantly decreased in RaKOCKD compared to all other groups. Thus, anemia appeared only in RaKO-CKD and not in WT-CKD. Systemic inflammation was higher in RaKO-CKD; leading to hepcidin mediated iron malabsorption, inhibited kidney HIF2 response and decreased bone marrow EPO-R. Reducing IL-1 effects may be an additional therapeutic strategy in CKD-associated anemia.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Inbar Bandach”
- BylineArticles whose byline prints “Daniel Landau”
- BylineArticles whose byline prints “Ron N Apte”
- BylineArticles whose byline prints “Yael Segev”
